Business Wire

Quinbrook Infrastructure Partners Launches with Mercatus

Share

Mercatus, a leading alternative asset and investment management platform, today announced the initial launch of Quinbrook Infrastructure Partners with the Mercatus Investment Lifecycle Management (ILM) Platform.

Quinbrook invests in a wide range of low carbon and renewable energy infrastructure assets spanning onshore wind, utility scale and distributed solar PV, battery storage, peaking capacity and ‘smart grids’. Quinbrook recently announced final close on its latest strategy securing over USD 1.6 billion from institutional investors to support ‘value add’ investments in the US, UK and Australian markets.

The Mercatus Investment Lifecycle Management (ILM) Platform systematizes and centralizes asset, fund, and portfolio data to give investors accurate analytics and real-time performance, risk, and ESG insights.

“Mercatus offered us the fastest time-to-value on our biggest need: streamlining how we work with our rapidly expanding stable of portfolio companies and preparing for the digital overhaul of our asset management capabilities. We launched within 3 months,” said David Scaysbrook, Co-Founder and Managing Partner at Quinbrook Infrastructure Partners. “Our goal is for Quinbrook to be counted amongst the most effective and operationally-focused investors and asset managers globally through real time access to actual performance data to better inform pro-active decision making and reporting. By using Mercatus to systematize the data and workflows across all our portfolio companies, we expect to achieve higher levels of scalability and managerial efficiency so we can grow faster and smarter and deliver tangible benefits for our investors in the process.”

Key Quinbrook requirements for a solution:

  1. Consistency – uniform, real-time data and reporting across all portfolio companies
  2. Efficiency – more time spent on managing investments, less time on reporting and administrative tasks
  3. Scalability – providing the infrastructure for every company to be self-sustainable for new growth
  4. Visibility – into risk, performance, and forward-looking valuations
  5. Operational Excellence – through automation and centralized data/model controls to reduce data accuracy risk and improve real time insights

“What really stands out is Quinbrook’s vision for gaining a competitive edge and leveraging cutting-edge techniques as a key differentiator to LPs as they compete with the top Global PE Funds,” said Haresh Patel, CEO at Mercatus. “Quinbrook sees the road ahead and understands what’s coming in both complexity and growth. They are creating a technology platform that aligns with their portfolio companies and LP’s by providing full visibility, traceability, and control of every piece of data and every insight derived. It’s exciting to see a company take full advantage of every piece of our platform to drive maximum value.”

Quinbrook is launching the Mercatus ILM Platform with five of the portfolio companies in its Low Carbon Power Fund. For more information about Mercatus ILM, visit www.gomercatus.com.

About Quinbrook

Quinbrook Infrastructure Partners (www.quinbrook.com) is a specialist investment manager focused exclusively on lower carbon and renewable energy infrastructure investment and operational asset management in the US, UK and Australia. Quinbrook is led and managed by a senior team of power industry professionals who have collectively invested over US$ 17 billion in energy infrastructure assets since the early 1990's, representing over 30GW of supply capacity. Quinbrook's investment and asset management team has offices in Houston, London, Jersey, and the Gold Coast of Australia. Quinbrook currently manages the Low Carbon Power Fund which has invested in wind, solar, battery storage, gas peaking and ‘smart grid’ businesses and also Cape Byron Power (www.capebyronpower.com), one of Australia's largest base-load 100% renewable power generators.

About Mercatus

Mercatus is the leading provider of alternative asset investment management solutions, helping investors maximize returns, accelerate growth, and mitigate risk. Mercatus is the only platform to systematically consolidate asset and portfolio data, automate and control financial analysis, and streamline decisions and collaboration across the entire investment lifecycle. Many of the largest global funds leverage Mercatus to manage over $450B of assets and investments across 118 countries and 11 asset classes. Mercatus is headquartered in Silicon Valley with offices in Europe and India. For more information, visit www.gomercatus.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Melanie Flanigan
415-971-1886
mflanigan@gomercatus.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 23:06:00 EEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 15:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye